Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.16
(-4.92%)
USD 1.16
(-4.92%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 81.44 Million USD | -28.68% |
| 2022 | 114.19 Million USD | 42.05% |
| 2021 | 80.38 Million USD | 21.07% |
| 2020 | 66.39 Million USD | 468.93% |
| 2019 | 11.67 Million USD | -21.62% |
| 2018 | 14.88 Million USD | -18.8% |
| 2017 | 18.33 Million USD | -18.61% |
| 2016 | 22.52 Million USD | -15.27% |
| 2015 | 26.58 Million USD | 251.27% |
| 2014 | 7.56 Million USD | 31.28% |
| 2013 | 5.76 Million USD | -0.4% |
| 2012 | 5.78 Million USD | 3859114.67% |
| 2011 | 150.00 USD | 0.0% |
| 2010 | 150.00 USD | -92.93% |
| 2009 | 2122.00 USD | -4.33% |
| 2008 | 2218.00 USD | -65.52% |
| 2007 | 6433.00 USD | 1280.47% |
| 2006 | 466.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 88.35 Million USD | 8.48% |
| 2024 Q2 | 89.86 Million USD | 1.71% |
| 2023 Q1 | 102.02 Million USD | -10.65% |
| 2023 FY | 81.44 Million USD | -28.68% |
| 2023 Q2 | 99.05 Million USD | -2.92% |
| 2023 Q3 | 88.94 Million USD | -10.2% |
| 2023 Q4 | 81.44 Million USD | -8.43% |
| 2022 Q3 | 116.81 Million USD | -4.09% |
| 2022 FY | 114.19 Million USD | 42.05% |
| 2022 Q2 | 121.8 Million USD | 63.35% |
| 2022 Q4 | 114.19 Million USD | -2.25% |
| 2022 Q1 | 74.56 Million USD | -7.25% |
| 2021 Q4 | 80.38 Million USD | -4.84% |
| 2021 Q3 | 84.47 Million USD | 0.03% |
| 2021 Q2 | 84.45 Million USD | 12.46% |
| 2021 Q1 | 75.09 Million USD | 13.1% |
| 2021 FY | 80.38 Million USD | 21.07% |
| 2020 FY | 66.39 Million USD | 468.93% |
| 2020 Q1 | 8.36 Million USD | -28.33% |
| 2020 Q3 | 50.52 Million USD | -9.71% |
| 2020 Q4 | 66.39 Million USD | 31.41% |
| 2020 Q2 | 55.95 Million USD | 569.03% |
| 2019 Q2 | 21.81 Million USD | 78.33% |
| 2019 Q3 | 16.31 Million USD | -25.21% |
| 2019 Q4 | 11.67 Million USD | -28.48% |
| 2019 FY | 11.67 Million USD | -21.62% |
| 2019 Q1 | 12.23 Million USD | -17.83% |
| 2018 FY | 14.88 Million USD | -18.8% |
| 2018 Q4 | 14.88 Million USD | -5.18% |
| 2018 Q3 | 15.7 Million USD | -30.47% |
| 2018 Q2 | 22.58 Million USD | -19.74% |
| 2018 Q1 | 28.14 Million USD | 53.46% |
| 2017 Q2 | 12.97 Million USD | -28.88% |
| 2017 FY | 18.33 Million USD | -18.61% |
| 2017 Q4 | 18.33 Million USD | -15.58% |
| 2017 Q3 | 21.72 Million USD | 67.39% |
| 2017 Q1 | 18.24 Million USD | -19.02% |
| 2016 Q1 | 23.34 Million USD | -12.2% |
| 2016 Q3 | 17.26 Million USD | -19.98% |
| 2016 Q2 | 21.57 Million USD | -7.59% |
| 2016 Q4 | 22.52 Million USD | 30.51% |
| 2016 FY | 22.52 Million USD | -15.27% |
| 2015 Q4 | 26.58 Million USD | 6.14% |
| 2015 Q2 | 26.33 Million USD | 31.29% |
| 2015 Q1 | 20.05 Million USD | 164.96% |
| 2015 Q3 | 25.04 Million USD | -4.86% |
| 2015 FY | 26.58 Million USD | 251.27% |
| 2014 Q2 | 15.44 Million USD | 135.47% |
| 2014 Q4 | 7.56 Million USD | -39.92% |
| 2014 Q3 | 12.59 Million USD | -18.44% |
| 2014 FY | 7.56 Million USD | 31.28% |
| 2014 Q1 | 6.55 Million USD | 13.78% |
| 2013 FY | 5.76 Million USD | -0.4% |
| 2013 Q4 | 5.76 Million USD | 42.36% |
| 2013 Q3 | 4.04 Million USD | -29.38% |
| 2013 Q2 | 5.73 Million USD | 70.82% |
| 2013 Q1 | 3.35 Million USD | -42.01% |
| 2012 FY | 5.78 Million USD | 3859114.67% |
| 2012 Q3 | 2.83 Million USD | 1993307.75% |
| 2012 Q2 | 142.00 USD | -5.33% |
| 2012 Q1 | 150.00 USD | 0.0% |
| 2012 Q4 | 5.78 Million USD | 104.51% |
| 2011 FY | 150.00 USD | 0.0% |
| 2011 Q4 | 150.00 USD | 0.0% |
| 2011 Q3 | 150.00 USD | 0.0% |
| 2011 Q2 | 150.00 USD | 0.0% |
| 2011 Q1 | 150.00 USD | 0.0% |
| 2010 Q1 | 1198.00 USD | -43.54% |
| 2010 FY | 150.00 USD | -92.93% |
| 2010 Q2 | 35.06 Thousand USD | 2826.88% |
| 2010 Q3 | 150.00 USD | -99.57% |
| 2010 Q4 | 150.00 USD | 0.0% |
| 2009 Q1 | 2194.00 USD | -1.08% |
| 2009 Q4 | 2122.00 USD | -1.12% |
| 2009 Q3 | 2146.00 USD | -1.11% |
| 2009 Q2 | 2170.00 USD | -1.09% |
| 2009 FY | 2122.00 USD | -4.33% |
| 2008 Q4 | 2218.00 USD | -1.07% |
| 2008 Q2 | 2266.00 USD | -1.05% |
| 2008 Q3 | 2242.00 USD | -1.06% |
| 2008 FY | 2218.00 USD | -65.52% |
| 2008 Q1 | 2290.00 USD | -64.4% |
| 2007 Q3 | 6432.00 USD | 1280.26% |
| 2007 FY | 6433.00 USD | 1280.47% |
| 2007 Q2 | 466.00 USD | 0.0% |
| 2007 Q1 | 466.00 USD | 0.0% |
| 2007 Q4 | 6433.00 USD | 0.02% |
| 2006 Q4 | 466.00 USD | 0.0% |
| 2006 FY | 466.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -320.231% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -1319.892% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 25.935% |
| Azitra, Inc. | 5.11 Million USD | -1492.126% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -715.347% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -84394.403% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -712.905% |
| CEL-SCI Corporation | 30.52 Million USD | -166.786% |
| iBio, Inc. | 28.73 Million USD | -183.445% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 19.377% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -976.339% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | -24.196% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -1763.045% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -801.539% |
| NanoViricides, Inc. | 12.82 Million USD | -535.155% |
| Oragenics, Inc. | 4.96 Million USD | -1539.942% |
| BiomX Inc. | 58.15 Million USD | -40.046% |
| BiomX Inc. | 58.15 Million USD | -40.046% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 3.54% |
| Palatin Technologies, Inc. | 10.74 Million USD | -658.173% |
| Scorpius Holdings, Inc. | 51.03 Million USD | -59.578% |